MEP76708A - (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker - Google Patents

(imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Info

Publication number: MEP76708A
Authority: ME; Montenegro
Prior art keywords: disease; compounds; pyridazine; imidazol; methyl
Prior art date: 2002-05-16

Application number

MEP-767/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Bernd Buettelmann

Neidhart Marie-Paule Heitz

Georg Jaeschke

Emmanuel Pinard

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-16

Filing date

2003-05-16

Publication date

2011-12-20

2003-05-16 Application filed filed Critical

2011-12-20 Publication of MEP76708A publication Critical patent/MEP76708A/xx

Links

GFSWLEBKUPUQNQ-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)pyridazine Chemical compound C1=CN=CN1CC1=CC=CN=N1 GFSWLEBKUPUQNQ-UHFFFAOYSA-N 0.000 title 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
230000004770 neurodegeneration Effects 0.000 abstract 3
208000002193 Pain Diseases 0.000 abstract 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
230000001684 chronic effect Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000035143 Bacterial infection Diseases 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
208000005298 acute pain Diseases 0.000 abstract 1
239000003513 alkali Substances 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
208000022362 bacterial infectious disease Diseases 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Addiction (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MEP-767/08A 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker MEP76708A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02010217		2002-05-16
PCT/EP2003/005151 WO2003097637A1 (en)	2002-05-16	2003-05-16	(imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Publications (1)

Publication Number	Publication Date
MEP76708A true MEP76708A (en)	2011-12-20

Family

ID=29433072

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-767/08A MEP76708A (en)	2002-05-16	2003-05-16	(imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Country Status (30)

Country	Link
US (1)	US7005432B2 (sr)
EP (1)	EP1506190B1 (sr)
JP (1)	JP4267569B2 (sr)
KR (1)	KR100632868B1 (sr)
CN (1)	CN1312151C (sr)
AR (1)	AR040010A1 (sr)
AT (1)	ATE329912T1 (sr)
AU (1)	AU2003242542B2 (sr)
BR (1)	BR0311177A (sr)
CA (1)	CA2485926C (sr)
CL (1)	CL2004001251A1 (sr)
CY (1)	CY1105159T1 (sr)
DE (1)	DE60306152T2 (sr)
DK (1)	DK1506190T3 (sr)
ES (1)	ES2265581T3 (sr)
HR (1)	HRP20041060B1 (sr)
IL (1)	IL164922A (sr)
MA (1)	MA27117A1 (sr)
ME (1)	MEP76708A (sr)
MX (1)	MXPA04011253A (sr)
NO (1)	NO329605B1 (sr)
NZ (1)	NZ536310A (sr)
PL (1)	PL211340B1 (sr)
PT (1)	PT1506190E (sr)
RS (1)	RS51200B (sr)
RU (1)	RU2317294C2 (sr)
SI (1)	SI1506190T1 (sr)
TN (1)	TNSN04224A1 (sr)
WO (1)	WO2003097637A1 (sr)
ZA (1)	ZA200408789B (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7005432B2 (en) *	2002-05-16	2006-02-28	Hoffman-La Roche Inc.	Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) *	2002-08-13	2002-09-25	Merck Sharp & Dohme	Therapeutic agents
CN100579579C (zh) *	2002-10-01	2010-01-13	诺华疫苗和诊断公司	抗癌及抗感染性疾病组合物及其使用方法
EP1888706B1 (de)	2005-05-03	2017-03-01	Merck Patent GmbH	Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate
US20090054392A1 (en) *	2007-08-20	2009-02-26	Wyeth	Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) *	2008-02-07	2013-10-16	セントラル硝子株式会社	１−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de)	2008-03-17	2009-09-24	Aicuris Gmbh & Co. Kg	Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US20110053951A1 (en) *	2008-03-27	2011-03-03	Evotec Neurosciences Gmbh	Methods for treating disorders using nmda nr2b-subtype selective antagonist
BRPI1008498B8 (pt)	2009-02-05	2021-05-25	Takeda Pharmaceuticals Co	compostos de piridazinona úteis como inibidores da fosfodiesterase 10a, composição farmacêutica, e, uso de um composto
EP2602255B1 (en) *	2010-08-04	2017-04-26	Takeda Pharmaceutical Company Limited	Fused heterocyclic ring compound
WO2012019106A2 (en) *	2010-08-06	2012-02-09	Board Of Regents Of The University Of Nebraska	Positive and negative modulators of nmda receptors
WO2013160728A1 (en)	2012-04-26	2013-10-31	Alma Mater Studiorum - Universita' Di Bologna	Dual targeting compounds for the treatment of alzheimer's disease
EP3180329B1 (en) *	2014-08-15	2020-03-18	Janssen Pharmaceuticals, Inc.	Triazoles as nr2b receptor inhibitors
DE102015011861B4 (de)	2015-09-10	2018-03-01	Rudolf Schindler	Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
ES2821010T3 (es)	2015-12-09	2021-04-23	Cadent Therapeutics Inc	Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
KR20180108822A (ko)	2016-02-10	2018-10-04	얀센 파마슈티카 엔.브이.	Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
BR112018016794B1 (pt)	2016-02-18	2022-07-19	Syngenta Participations Ag	Compostos derivados de pirazol ativos em termos pesticidas, composição pesticida, método para controle de pragas, método para a proteção de material de propagação vegetal do ataque por pragas e material de propagação vegetal
WO2017158147A1 (en)	2016-03-18	2017-09-21	Savira Pharmaceuticals Gmbh	Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en)	2016-03-18	2017-09-21	Savira Pharmaceuticals Gmbh	Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh)	2016-10-06	2018-06-01	比利時商健生藥品公司	經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
AU2017382339B2 (en)	2016-12-22	2024-02-15	Novartis Ag	NMDA receptor modulators and uses thereof
EP3774732A4 (en)	2018-04-04	2022-02-09	Janssen Pharmaceutica NV	PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
PT3830092T (pt)	2018-08-03	2023-07-25	Novartis Ag	Moduladores do recetor nmda heteroaromáticos e suas utilizações
US20220324860A1 (en)	2019-06-14	2022-10-13	Janssen Pharmaceutica Nv	SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020291188A1 (en)	2019-06-14	2022-01-20	Janssen Pharmaceutica Nv	Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
EP3983413A1 (en)	2019-06-14	2022-04-20	Janssen Pharmaceutica NV	Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
JP7667097B2 (ja)	2019-06-14	2025-04-22	ヤンセンファーマシューティカエヌ．ベー．	置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
SG11202112407PA (en)	2019-06-14	2021-12-30	Janssen Pharmaceutica Nv	Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
BR112021025132A2 (pt)	2019-06-14	2022-01-25	Janssen Pharmaceutica Nv	Carbamatos de piridina e seu uso como moduladores do receptor glun2b
AU2020290772A1 (en)	2019-06-14	2022-01-06	Janssen Pharmaceutica Nv	Pyrazine carbamates and their use as GluN2B receptor modulators
CN114478210A (zh) *	2022-02-26	2022-05-13	江苏壹药新材料有限公司	一种7-氯萘-2-甲醛的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4010797A1 (de) *	1990-04-04	1991-10-10	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
TR199801774T2 (xx) *	1996-03-08	1998-12-21	F.Hoffmann-La Roche Ag	4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
CA2220649C (en)	1996-12-03	2007-02-13	F. Hoffmann-La Roche Ag	4-hydroxy-piperidine derivatives
US6015824A (en) *	1998-02-10	2000-01-18	Hoffmann-La Roche Ag	Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en)	1999-06-08	2006-05-01	Hoffmann La Roche	Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de)	1999-07-21	2004-01-15	Hoffmann La Roche	Triazolderivate
US6339093B1 (en)	1999-10-08	2002-01-15	Hoffmann-La Roche Inc.	Isoquinoline derivatives
JP4219590B2 (ja)	2000-04-20	2009-02-04	エフ．ホフマン−ラロシュアーゲー	ピロリジン及びピペリジン誘導体並びに神経変性障害の治療のためのこれらの使用
US6432985B2 (en)	2000-04-25	2002-08-13	Hoffmann-La Roche Inc.	Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2001296994A1 (en)	2000-10-06	2002-04-15	Regents Of The University Of California	Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en)	2001-04-23	2002-10-23	Leonard Theodore Meltzer	Method for preventing dyskinesias
DE10120159A1 (de)	2001-04-25	2002-10-31	Merck Patent Gmbh	NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) *	2002-05-16	2006-02-28	Hoffman-La Roche Inc.	Substituted imidazol-pyridazine derivatives

2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 CA CA002485926A patent/CA2485926C/en not_active Expired - Fee Related
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active Expired - Fee Related
- 2003-05-16 EP EP03752750A patent/EP1506190B1/en not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/en not_active Ceased
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
2006
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown

Also Published As

Publication number	Publication date
PT1506190E (pt)	2006-11-30
BR0311177A (pt)	2005-03-15
RU2004136979A (ru)	2005-07-10
CA2485926A1 (en)	2003-11-27
TNSN04224A1 (fr)	2007-03-12
HK1080845A1 (en)	2006-05-04
HRP20041060B1 (en)	2012-11-30
RS98504A (sr)	2006-12-15
ZA200408789B (en)	2005-12-28
RS51200B (sr)	2010-12-31
MA27117A1 (fr)	2004-12-20
US20030229096A1 (en)	2003-12-11
ES2265581T3 (es)	2007-02-16
DE60306152D1 (de)	2006-07-27
WO2003097637A1 (en)	2003-11-27
AU2003242542B2 (en)	2008-10-16
NO329605B1 (no)	2010-11-22
DE60306152T2 (de)	2007-04-26
PL374224A1 (en)	2005-10-03
CN1653062A (zh)	2005-08-10
MXPA04011253A (es)	2005-01-25
CY1105159T1 (el)	2009-11-04
SI1506190T1 (sl)	2006-10-31
JP4267569B2 (ja)	2009-05-27
CN1312151C (zh)	2007-04-25
CL2004001251A1 (es)	2005-04-22
NZ536310A (en)	2007-08-31
KR20040106558A (ko)	2004-12-17
JP2005532326A (ja)	2005-10-27
CA2485926C (en)	2009-11-24
IL164922A (en)	2012-01-31
PL211340B1 (pl)	2012-05-31
IL164922A0 (en)	2005-12-18
EP1506190B1 (en)	2006-06-14
ATE329912T1 (de)	2006-07-15
AR040010A1 (es)	2005-03-09
NO20044666L (no)	2004-12-15
HRP20041060A2 (en)	2005-06-30
US7005432B2 (en)	2006-02-28
DK1506190T3 (da)	2006-10-16
EP1506190A1 (en)	2005-02-16
RU2317294C2 (ru)	2008-02-20
AU2003242542A1 (en)	2003-12-02
KR100632868B1 (ko)	2006-10-13

Publication	Publication Date	Title
CY1105159T1 (el)	2009-11-04	(ιμιδαζολ-1-υλο-μεθυλο)-πυριδαζινη ως παρεμποδιστης υποδοχεα νμda
MA31593B1 (fr)	2010-08-02	Derives de 2-aza-bicyclo[3.3.0]octane
NZ609221A (en)	2014-11-28	Benzoxazole kinase inhibitors and methods of use
DE60336850D1 (en)	2011-06-01	Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
EP2039687A4 (en)	2010-09-08	THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS
MX2010002098A (es)	2010-03-30	Compuesto policiclico.
WO2002060879A3 (en)	2003-03-27	Bacterial gyrase inhibitors and uses thereof
MA32558B1 (fr)	2011-08-01	Composes organiques
MA32151B1 (fr)	2011-03-01	Derives de 2-aza-bicyclo[2.2.1]heptane
NO20074311L (no)	2007-11-23	Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
MA30703B1 (fr)	2009-09-01	Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
WO2001081309A3 (en)	2002-01-17	4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
TNSN03140A1 (fr)	2005-12-23	Derives d'acides sulfoniques nouveaux.
MX344556B (es)	2016-12-20	Agonista de subtipo de receptor 5-ht1a.
WO2006090273A3 (en)	2006-10-05	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2007096740A3 (en)	2007-10-18	Novel cephalosporins
MA31742B1 (fr)	2010-10-01	Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
PT2000473E (pt)	2011-07-01	Composto de trealose e preparação farmacêutica que contém esse composto
EA014959B3 (ru)	2014-10-30	Ингибиторы глицинового переносчика-1
MX384745B (es)	2025-03-14	Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
MX2009011449A (es)	2010-01-25	Agente terapeutico o profilactico para disquinesia.
YU86501A (sh)	2004-09-03	Derivati etansulfonil-piperidina
WO2007017728A3 (en)	2008-04-03	Novel heterocyclic compounds
WO2008141097A3 (en)	2008-12-31	Stereoisomers propofol therapeutic compounds
WO2008099781A1 (ja)	2008-08-21	アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤